Sugi Predict

Sugi Predict / Compounds / SCHEMBL2176445

SCHEMBL2176445

SCHEMBL2176445

CC(=O)N1CC[C@H](C(=O)N2CCN(c3ccc(C#N)cc3C)CC2)[C@@H](C(=O)O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 2/20 0.41
▸ CTSK P43235 2/20 0.41
▸ ADAM10 O14672 4/20 0.41
▸ MMP2 P08253 2/20 0.41
▸ MMP9 P14780 2/20 0.41
▸ MMP14 P50281 2/20 0.41
▸ ADAM17 P78536 2/20 0.41
▸ AR P10275 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.39
▸ MC4R P32245 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SLC6A9 P48067 1/20 0.36
▸ SLC6A5 Q9Y345 1/20 0.36
▸ RORC P51449 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456406 0.93 CTSK (0.42) CTSSCTSKADAM10MMP2MMP9
SCHEMBL2176442 0.89 CTSK (0.42) CTSSCTSKADAM10MMP2MMP9
SCHEMBL3456872 0.85 CTSK (0.40) CTSSCTSKADAM10MMP2MMP9
SCHEMBL3456876 0.85 CTSK (0.40) CTSSCTSKADAM10MMP2MMP9
SCHEMBL6024520 0.85 CTSK (0.40) CTSSCTSKADAM10MMP2MMP9
SCHEMBL3456962 0.83 CTSK (0.42) CTSSCTSKADAM10MMP2MMP9
SCHEMBL6024319 0.83 POLB (0.37) CTSSCTSKADAM10MMP2MMP9
SCHEMBL3456956 0.83 POLB (0.37) CTSSCTSKADAM10MMP2MMP9
SCHEMBL3456952 0.83 POLB (0.37) CTSSCTSKADAM10MMP2MMP9
SCHEMBL532719 0.77 HTT (0.49) ADAM10MMP2MMP9MMP14ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 CTSS 37/4885CTSK 74/4885ADAM10 25/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 CTSS 42/4885CTSK 76/4885ADAM10 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.